Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report.

Lina WangXiaolin ZhangBo HuangYue HouXinmin LiuHongmei Jiao

Published in: Infection and drug resistance (2023)

Clinicians should be aware of the possibility of HLH secondary to mild SARS-CoV-2 infection and take timely therapeutic measures to inhibit an inflammatory factor storm. Ruxolitinib is a potential choice for COVID-19 related HLH.

Keyphrases

respiratory syndrome coronavirus
sars cov
coronavirus disease
palliative care
risk assessment
climate change
decision making
human health